Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ophtha.2003.06.007
Title: Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma
Authors: Chew, P.T.K. 
Aung, T. 
Aquino, M.V.
Rojanapongpun, P.
Issue Date: 2004
Source: Chew, P.T.K., Aung, T., Aquino, M.V., Rojanapongpun, P. (2004). Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology 111 (3) : 427-434. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ophtha.2003.06.007
Abstract: Objective: To demonstrate that the intraocular pressure (IOP)-reducing effect of latanoprost once daily is at least as good as that of timolol twice daily in patients with chronic angle-closure glaucoma (CACG). Design: Randomized, double-masked, multicenter 12-week study. Participants: In all, 137 patients with unilateral or bilateral CACG were treated with latanoprost, and 138 were treated with timolol. Methods: Patients received either latanoprost (9 PM) and a placebo (9 AM) or timolol (both 9 AM and 9 PM). Intraocular pressure was measured at 9 AM and 5 PM at baseline and weeks 2, 6, and 12. Main Outcome Measures: The difference between groups in daily IOP (average of 9 AM and 5 PM measures) reduction was the primary outcome. Secondary outcomes included differences between groups in IOP reductions at 9 AM and 5 PM, and in proportions of patients reaching specified daily IOP levels. Results: Using repeated measures (analysis of covariance: intent to treat), mean changes from baseline in daily IOP levels during 12 weeks were -8.2 mmHg and -5.2 mmHg for latanoprost- and timolol-treated patients, respectively (difference: -3.0 mmHg [95% confidence interval: -4.0, -2.1], P<0.001). Greater reductions in IOP levels at both 9 AM and 5 PM were found in latanoprost-treated patients (P<0.001 for both), and greater proportions of patients receiving latanoprost reached prespecified target daily IOP levels (P<0.001 for all 3 target levels tested). Both drugs were well tolerated. Conclusion: Latanoprost administered once daily provides significantly greater IOP reduction in CACG patients than does timolol instilled twice daily. © 2004 by the American Academy of Ophthalmology.
Source Title: Ophthalmology
URI: http://scholarbank.nus.edu.sg/handle/10635/29100
ISSN: 01616420
DOI: 10.1016/j.ophtha.2003.06.007
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

49
checked on Dec 14, 2017

WEB OF SCIENCETM
Citations

34
checked on Nov 18, 2017

Page view(s)

133
checked on Dec 10, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.